In its oversubscribed, concurrent share offering, medmix set the offer price of its new shares at CHF 45 per share. Besides Switzerland, strong institutional investor demand came from the UK, France, Canada and USA. Based on a final offer size of 7'000'000 new shares, medmix has raised gross proceeds of CHF 315 million from the capital increase, yielding net proceeds of approximately CHF 295.2 million. The net proceeds will be used to finance organic and inorganic growth initiatives and for general corporate purposes. As previously announced, medmix' reference shareholder Tiwel Holding did not participate in the share offering, resulting in a free float of medmix of close to 60%. As a result of the capital increase, the number of issued shares of medmix will increase by 7 million registered shares to 41'262'370 registered shares with a par value of CHF 0.01 each, corresponding to a total market capitalisation of close to CHF 1.9 billion at the final offer price. This step completes the spin-off of Sulzer's Applicator Systems division, which has been renamed medmix and is a global leader in high-precision delivery devices.

The listing and first day of trading of medmix shares on SIX Swiss Exchange is today, September 30, 2021. Settlement and delivery of the new shares issued in the capital increase against payment of the offer price is expected to occur on October 4, 2021.

Credit Suisse AG and UBS AG have acted as exclusive financial advisors to Sulzer in the context of the spin-off.

Attachments

  • Original document
  • Permalink

Disclaimer

Sulzer AG published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 12:53:04 UTC.